Novo Nordisk Names Jørgensen CEO As Sørensen Steps Down Early
Executive Summary
Lars Rebien Sørensen is retiring as CEO of Novo Nordisk by the end of the year, with executive vice president and corporate development head Lars Fruergaard Jørgensen stepping up as his successor.
You may also be interested in...
"Take More Risks, Fail Earlier" Says Asset-Hunting Novo Nordisk CEO
Novo Nordisk's CEO tells Scrip why the Danish group's R&D approach must embrace risk earlier to ensure "differentiated" products in an increasingly competitive world.
Big Pharma May 2017: Product Developments Shift Stock
In a new monthly column, Scrip rounds up events on the stock market, noting trends and exceptional performance both good and bad. This month, the focus is on 30 biopharma companies with market caps above $10bn. Between them, these 30 companies account for approximately 75% of the asset value in the pharmaceutical industry.
Spring Break: Novo's US Head Resigns After Rough Winter
Novo Nordisk's executive VP and head of North American operations, Jakob Riis, has resigned from the company – a move not completely out of the blue considering recent rumors of conflict within the diabetes drug developer's US operations and a lackluster 2016 financial performance for the whole group.